Amplify Weight Loss Drug & Treatment ETF

Amplify Weight Loss Drug & Treatment ETF is offered by Amplify, a leading player in the field of passive investments.

The total expense ratio of Amplify Weight Loss Drug & Treatment ETF is 0.59%, which means that investors pay 59 USD per 10,000 USD in investment capital annually.

The ETF is listed in USD.

European investors may incur additional costs for currency exchange and transaction fees.

No, Amplify Weight Loss Drug & Treatment ETF does not comply with the EU UCITS investor protection directives.

The P/E ratio of Amplify Weight Loss Drug & Treatment ETF is 20.66.

Amplify Weight Loss Drug & Treatment ETF tracks the performance of the VettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net.

The current average trading volume of Amplify Weight Loss Drug & Treatment ETF is 3,346.93.

Amplify Weight Loss Drug & Treatment ETF is domiciled in US.

The fund was launched on 5/21/2024.

The Amplify Weight Loss Drug & Treatment ETF mainly invests in Healthcare companies.

The NAV of Amplify Weight Loss Drug & Treatment ETF amounts to 26.49 M USD.

The price-to-book ratio is 5.617.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.